Novartis Confronts Entresto Decline as Valuation Risks Mount

What happened

Novartis stock peaked at a 52-week high of $170.46 in February 2025, capping a strong rally driven by robust sales growth and margin expansion. A correction ensued, partly attributed to a 33.2% quarter-over-quarter drop in Entresto sales to $1.25 billion in Q4, marking the tangible onset of generic erosion. The DeepValue report underscores that the stock trades at a premium ~19.5x P/E, pricing in a seamless offset of this loss of exclusivity by high-growth brands like Kisqali and Kesimpta. Market sentiment has shifted from optimism to caution, with recent downgrades reflecting concerns over visible LOE headwinds and margin pressures from acquisitions like Avidity. Despite solid cash flows, the risk-reward appears unfavorable, with the bear scenario implying a ~17% downside to $120 if growth brands stumble.

Implication

The sharp Entresto sales drop confirms that generic erosion is no longer a forward-looking risk but an immediate headwind, challenging management's 5-6% sales CAGR guidance. At current premium valuations, any slippage in growth brands like Kisqali or margin compression from M&A could trigger a re-rating toward sector averages, compressing the P/E. Monitor Q1 2026 results for updated guidance on sales growth and core margins, with sub-5% growth or margins below 38% signaling thesis breakers. The concentrated reliance on oncology and neurology assets heightens execution risk, making the stock vulnerable to pipeline setbacks or competitive pressures. Given the skewed risk-reward and crowded sentiment, existing holders should consider reducing exposure, while new capital is better deployed elsewhere until clearer signs of sustainable offset emerge.

Thesis delta

The article's report of a 33.2% QoQ Entresto sales decline strengthens the DeepValue report's bear case, shifting the LOE narrative from a managed transition to an accelerating threat. This increases the urgency for growth brands to deliver outperformance, as the margin of safety narrows with the stock still at premium multiples. Investors must now price in higher probability of sales growth falling short of guidance, necessitating a reassessment of entry points near the $125 attractive level cited in the report.